lamivudine has been researched along with rilpivirine in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.00) | 29.6817 |
| 2010's | 21 (52.50) | 24.3611 |
| 2020's | 17 (42.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Daelemans, D; De Clercq, E; Kang, D; Liu, X; Pannecouque, C; Tian, Y; Wang, Z; Yu, Z; Zhan, P; Zhang, J | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Adams, E; Baert, L; Hoogmartens, J; Pendela, M; Rosier, J; Van den Mooter, G; Van Gyseghem, E | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Klinbuayaem, V; Munsakul, W; Petoumenos, K; Prasithsirikul, W; Ruxrungtham, K; Sirivichayakul, S; Sungkanuparph, S | 1 |
| Arasteh, K; Boven, K; Crauwels, H; De Wet, J; Gathe, J; Gold, J; Hodder, S; Kumar, P; Mohapi, L; Short, W; Vanveggel, S | 1 |
| Arribas, J; Deckx, H; Duiculescu, D; Florence, E; Hung, CC; Sension, M; Stevens, M; Tebas, P; Vanveggel, S; Wilkin, T | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| González-Domenech, CM; Hernández-Quero, J; Martínez, MA; Mayorga, ML; Olalla, J; Omar, M; Palacios, R; Pérez-Camacho, I; Pérez-Hernández, IA; Romero, A; Romero, JM; Santos, J | 1 |
| Ascione, T; Boccia, G; Carleo, MA; De Caro, F; Pagliano, P; Tortora, F | 1 |
| Barrufet, P; Berenguer, J; Boix, V; Carrero, A; Castaño, M; Esteban, H; Galindo, MJ; González-García, J; Hontañón, V; Imaz, A; Knobel, H; Moreno, S; Podzamczer, D; Raffo, M; Ribera, E; Ryan, P; Solís, J; Suárez-Lozano, I; Terrón, JA; Troya, J; Yllescas, M | 1 |
| Cattaneo, D; Clementi, E; Cozzi, V; Galli, M; Gervasoni, C; Meraviglia, P; Minisci, D; Riva, A | 1 |
| Ahmad, S; Brima, N; Chaponda, M; Davies, C; Hay, P; Johnson, M; Kingston, M; Lewis, JM; Marshall, N; Mulka, L; Muqbill, G; Nelson, M; Shaw, J; Smith, C; Tomkins, A; Torkington, A; Waters, L; Williams, D | 1 |
| Ceckova, M; Cerveny, L; Martinec, O; Ptackova, Z; Reznicek, J; Staud, F; Tupova, L | 1 |
| Angel, JB; Clair, MS; Clotet, B; Crauwels, H; Dorey, D; Eron, JJ; Ford, SL; Gonzalez-Garcia, J; Griffith, SK; Gutierrez, F; Lutz, T; Margolis, DA; Mrus, J; Murray, M; Patel, P; Podzamczer, D; Richmond, GJ; Sloan, L; Smith, KY; Spreen, WR; Stellbrink, HJ; Sutton, KC; Williams, PE; Yazdanpanah, Y | 1 |
| Brenner, BG; Ibanescu, RI; Mesplède, T; Oliveira, M; Wainberg, MA; Xu, H | 1 |
| Boswell, R; Foisy, MM; Hughes, CA | 1 |
| Bigoloni, A; Carini, E; Castagna, A; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Mancusi, D; Nozza, S; Poli, A; Tambussi, G; Termini, R | 1 |
| Agher, R; Calvez, V; Katlama, C; Marcelin, AG; Nguyen, T; Nouchi, A; Sayon, S; Simon, A; Soulie, C; Valantin, MA | 1 |
| Baldin, G; Capetti, A; Ciccullo, A; Colafigli, M; Cossu, MV; d'Ettorre, G; De Luca, A; Di Giambenedetto, S; Giacomelli, A; Lagi, F; Modica, S; Restelli, S; Rusconi, S; Sterrantino, G | 1 |
| Cabello, A; Cañamares, I; Cuevas, G; Matarranz, M; Montejano, R; Ryan, P; Solís, J; Troya, J; Walther, LÁ | 1 |
| Fujiwara, T; Kawauchi-Miki, S; Miki, S; Seki, T; Yoshinaga, T | 1 |
| Cento, V; Perno, CF | 1 |
| Aboud, M; Brown, D; de Ruiter, A; Demarest, J; Gatell, JM; Henegar, C; Quercia, R; Ragone, L; St Clair, M; Underwood, M; van Wyk, J; Vannappagari, V | 1 |
| Baldin, G; Borghetti, A; Borghi, V; Brescini, L; Capetti, A; Celani, L; Ciccullo, A; Colafigli, M; Cossu, MV; Di Giambenedetto, S; Dusina, A; Gennari, W; Giacomelli, A; Lagi, F; Latini, A; Madeddu, G; Mussini, C; Restelli, S; Rossetti, B; Rusconi, S; Sterrantino, G; Vignale, F | 1 |
| Bossolasco, S; Castagna, A; Cinque, P; Dell'Acqua, R; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Mastrangelo, A; Muccini, C; Poli, A | 1 |
| Ho, S; Lee, CC; Leo, YS; Lye, DCB; Ng, OT; Wong, CS; Wong, JG | 1 |
| Fida, M; Mahmood, M; Temesgen, Z | 1 |
| Allavena, C; Bani-Sadr, F; Cabie, A; Cuzin, L; Deschanvres, C; Duvivier, C; Hocqueloux, L; Joly, V; Lamaury, I; Palich, R; Raffi, F; Rey, D; Reynes, J; Robineau, O | 1 |
| Bartoloni, A; Borchi, B; Botta, A; Cavallo, A; Kiros, ST; Lagi, F; Meli, M; Pozzi, M; Sterrantino, G | 1 |
| Ang, JH; Ang, LW; Hoo, GS; Law, HL; Lee, CC; Leo, YS; Lim, ZC; Ng, OT; Teng, CB; Wong, CS | 1 |
| Baccini, M; Borghetti, A; Borghi, V; Callegaro, A; Dreassi, E; Gagliardini, R; Lodi, MA; Lombardi, F; Micheli, V; Modica, S; Montagnani, F; Pecorari, M; Rossetti, B; Zanelli, G; Zazzi, M | 1 |
| Alejos, B; Antonio Iribarren, J; Asensi, V; Galera, CE; García Yubero, C; Jarrín, I; Muñoz, A; Pascual-Carrasco, M; Pasquau, F; Riera Jaume, M; Ruiz-Algueró, M; Suárez-García, I | 1 |
| Allard, SD; Ausselet, N; Darcis, G; De Scheerder, MA; De Wit, S; Delforge, M; Demeester, R; Florence, E; Henrard, S; Loeckx, M; Messiaen, P; Nasreddine, R; Yombi, JC | 1 |
| Buzón, L; Dueñas, C; Pedrero-Tomé, R; Troya, J | 1 |
| Antinori, S; Baldin, G; Borghi, V; Capetti, A; Ciccullo, A; Cossu, MV; Di Giambenedetto, S; Farinacci, D; Giacomelli, A; Iannone, V; Lagi, F; Mussini, C; Passerotto, RA; Sterrantino, G | 1 |
| Derkach, EV; Pyadushkina, EA | 1 |
| Buzón, L; De la Fuente, S; De Los Santos, I; Dueñas-Gutiérrez, C; Ferreira, E; Gómez, J; Iribarren, JA; Moran, MA; Moreno, E; Pedrero-Tomé, R; Pousada, G; Troya, J | 1 |
| Brenner, BG; Ibanescu, RI; Oliveira, M; Routy, JP; Thomas, R | 1 |
| Antinori, S; Borghi, V; Ciccullo, A; D'Ettorre, G; De Vito, A; Di Giambenedetto, S; Ducci, F; Giacomelli, A; Giacometti, A; Lagi, F; Madeddu, G; Mussini, C; Pincino, R; Sterrantino, G; Taramasso, L | 1 |
6 review(s) available for lamivudine and rilpivirine
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
Topics: Acetamides; Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Prodrugs; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2019 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Observational Studies as Topic; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rilpivirine | 2018 |
Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Drug Substitution; HIV Infections; HIV-1; Humans; Lamivudine; Raltegravir Potassium; Rilpivirine; Treatment Outcome; Viral Load | 2019 |
Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; Equivalence Trials as Topic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Sustained Virologic Response | 2020 |
Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Genome, Viral; Global Health; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Prevalence; Rilpivirine; Treatment Outcome | 2019 |
4 trial(s) available for lamivudine and rilpivirine
| Article | Year |
|---|---|
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Stavudine | 2011 |
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black or African American; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Sex Factors; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Young Adult; Zidovudine | 2014 |
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Female; Global Health; HIV Infections; HIV-1; Humans; Injections, Intramuscular; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Viral Load | 2017 |
30 other study(ies) available for lamivudine and rilpivirine
| Article | Year |
|---|---|
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Development of a liquid chromatographic assay for an anti-HIV tablet containing lamivudine, zidovudine and TMC278.HCL.
Topics: Anti-HIV Agents; Biological Assay; Calibration; Chemistry, Pharmaceutical; Chromatography, Liquid; HIV; Humans; Lamivudine; Light; Molecular Structure; Nitriles; Pyrimidines; Reference Standards; Rilpivirine; Scattering, Radiation; Sensitivity and Specificity; Solvents; Spectrophotometry, Ultraviolet; Tablets; Zidovudine | 2009 |
Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Substitution; Female; HIV Infections; Humans; Lamivudine; Lipids; Male; Middle Aged; Rilpivirine; Treatment Outcome; Viral Load | 2016 |
HIV positive patient with HSV-2 encephalitis: case report.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Substitution; Encephalitis, Herpes Simplex; Herpesvirus 2, Human; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Rilpivirine; Ritonavir; Virus Replication | 2016 |
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Depression; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Lipids; Liver; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Treatment Outcome | 2016 |
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Viral Load | 2017 |
Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir; United Kingdom; Viral Load | 2017 |
MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Caco-2 Cells; Cell Line; Cell Line, Tumor; Dideoxynucleosides; Dogs; Drug Interactions; Humans; Intestinal Absorption; Lamivudine; Madin Darby Canine Kidney Cells; Male; Membrane Transport Proteins; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors; Rilpivirine | 2017 |
M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.
Topics: Amino Acid Substitution; Anti-HIV Agents; Clinical Trials as Topic; Deoxyadenosines; Drug Resistance, Viral; Emtricitabine; HEK293 Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutagenesis, Site-Directed; Mutation; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication | 2017 |
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Linear Models; Male; Middle Aged; Retrospective Studies; Rilpivirine; Time Factors; Treatment Failure; Viral Load | 2018 |
Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART.
Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Evolution, Molecular; Female; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; RNA, Viral | 2018 |
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol; Cohort Studies; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rilpivirine; Viral Load | 2019 |
Barrier to Resistance of Dolutegravir in Two-Drug Combinations.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine | 2019 |
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Italy; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rilpivirine; Treatment Outcome | 2019 |
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome | 2020 |
Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Rilpivirine; Singapore; Viral Load | 2020 |
Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Rilpivirine | 2020 |
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Rilpivirine; Viral Load | 2021 |
Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Immunocompromised Host; Italy; Lamivudine; Male; Middle Aged; Rilpivirine; Treatment Outcome | 2022 |
Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS).
Topics: Anti-HIV Agents; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Rilpivirine; Singapore | 2021 |
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
Topics: Anti-HIV Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Mutation; Oxazines; Piperazines; Pyridones; Rilpivirine | 2022 |
Use of Generic Antiretroviral Drugs and Single-Tablet Regimen De-Simplification for the Treatment of HIV Infection in Spain.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Lamivudine; Rilpivirine; Spain; Tablets | 2022 |
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Topics: Anti-HIV Agents; Belgium; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Rilpivirine; Treatment Outcome | 2023 |
A predictive model of immune recovery for DTG + 3TC and DTG + RPV used as switching strategies in HIV+ patients.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Rilpivirine | 2022 |
Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Rilpivirine | 2022 |
[The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation].
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Essential; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Rilpivirine; Tenofovir | 2021 |
Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
Topics: Anti-HIV Agents; Drug-Related Side Effects and Adverse Reactions; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Retrospective Studies; Rilpivirine | 2023 |
Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Rilpivirine | 2023 |
Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Retrospective Studies; Reverse Transcriptase Inhibitors; Rilpivirine | 2023 |